Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience

Published:2018-08 Issue:8 Volume:93 Page:1074-1081
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Ganzel Chezi¹^ORCID,Sun Zhuoxin²,Cripe Larry D.³,Fernandez Hugo F.⁴,Douer Dan⁵,Rowe Jacob M.¹⁶,Paietta Elisabeth M.⁷,Ketterling Rhett⁸,O'Connell Michael J.⁸,Wiernik Peter H.⁹,Bennett John M.¹⁰,Litzow Mark R.⁸,Luger Selina M.¹¹,Lazarus Hillard M.¹²,Tallman Martin S.⁵

Affiliation:

1. Shaare Zedek Medical Center; Jerusalem Israel

2. Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center; Boston Massachusetts

3. Indiana University Cancer Center; Indianapolis Indiana

4. H. Lee Moffitt Cancer Institute; Tampa Florida

5. Memorial Sloan Kettering Cancer; New York New York

6. Rambam Medical Center; Haifa Israel

7. Montefiore Medical Center; Bronx New York

8. Mayo Clinic; Rochester Minnesota

9. Beth Israel Medical Center; New York New York

10. University of Rochester Medical Center; Rochester New York

11. University of Pennsylvania; Philadelphia Pennsylvania

12. Case Western Reserve University, Case Comprehensive Cancer Center; Cleveland Ohio

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25162/fullpdf

Reference20 articles.

1. Prognostic index for adult patients with acute myeloid leukemia in first relapse;Breems;J Clin Oncol.,2005

2. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission;Burnett;J Clin Oncol.,2013

3. Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia;Araki;Haematologica.,2015

4. Varying intensity of postremission therapy in acute myeloid leukemia;Cassileth;Blood.,1992

5. Autologous bone marrow transplant in acute myeloid leukemia in first remission;Cassileth;J Clin Oncol.,1993

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia;Leukemia Research;2024-10

2. Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study;Leukemia & Lymphoma;2024-08-11

3. Contemporary Management of Acute Myeloid Leukemia;JAMA Oncology;2024-08-08

4. Discovery of NFκB2-Coordinated Dual Regulation of Mitochondrial and Nuclear Genomes Leads to an Effective Therapy for Acute Myeloid Leukemia;International Journal of Molecular Sciences;2024-08-05

5. The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience;Annals of Hematology;2024-07-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3